163 related articles for article (PubMed ID: 34041039)
1. Retraction: CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer.
Frontiers Editorial Office
Front Oncol; 2021; 11():694036. PubMed ID: 34041039
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer.
Lu T; Zhang L; Zhu W; Zhang Y; Zhang S; Wu B; Deng N
Front Oncol; 2020; 10():1529. PubMed ID: 32984003
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells.
Huo W; Zhao G; Yin J; Ouyang X; Wang Y; Yang C; Wang B; Dong P; Wang Z; Watari H; Chaum E; Pfeffer LM; Yue J
J Cancer; 2017; 8(1):57-64. PubMed ID: 28123598
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of
Cui Y; Wu BO; Flamini V; Evans BAJ; Zhou D; Jiang WG
Anticancer Res; 2017 Aug; 37(8):4415-4424. PubMed ID: 28739735
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
6. Knockout of
Zhu W; Liu C; Lu T; Zhang Y; Zhang S; Chen Q; Deng N
Front Oncol; 2020; 10():1451. PubMed ID: 32983976
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated noncoding RNA editing in human cancers.
Yang J; Meng X; Pan J; Jiang N; Zhou C; Wu Z; Gong Z
RNA Biol; 2018 Jan; 15(1):35-43. PubMed ID: 29028415
[TBL] [Abstract][Full Text] [Related]
8. Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing.
Garcia B; Lee J; Edraki A; Hidalgo-Reyes Y; Erwood S; Mir A; Trost CN; Seroussi U; Stanley SY; Cohn RD; Claycomb JM; Sontheimer EJ; Maxwell KL; Davidson AR
Cell Rep; 2019 Nov; 29(7):1739-1746.e5. PubMed ID: 31722192
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9.
He ZY; Zhang YG; Yang YH; Ma CC; Wang P; Du W; Li L; Xiang R; Song XR; Zhao X; Yao SH; Wei YQ
Hum Gene Ther; 2018 Feb; 29(2):223-233. PubMed ID: 29338433
[TBL] [Abstract][Full Text] [Related]
10. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
[TBL] [Abstract][Full Text] [Related]
11. Retraction: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
Frontiers Editorial Office
Front Oncol; 2020; 10():714. PubMed ID: 32373542
[TBL] [Abstract][Full Text] [Related]
12. Retraction: A novel tumor suppressor gene, ZFN24, inhibits the development of NSCLC by inhibiting the Wnt signaling pathway to induce cell senescence.
Frontiers Editorial Office
Front Oncol; 2022; 12():1045516. PubMed ID: 36237304
[TBL] [Abstract][Full Text] [Related]
13. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.
Jiang C; Meng L; Yang B; Luo X
Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells.
Yuen KS; Chan CP; Wong NM; Ho CH; Ho TH; Lei T; Deng W; Tsao SW; Chen H; Kok KH; Jin DY
J Gen Virol; 2015 Mar; 96(Pt 3):626-636. PubMed ID: 25502645
[TBL] [Abstract][Full Text] [Related]
15. Chemical transformation mediated CRISPR/Cas9 genome editing in Escherichia coli.
Sun D; Wang L; Mao X; Fei M; Chen Y; Shen M; Qiu J
Biotechnol Lett; 2019 Feb; 41(2):293-303. PubMed ID: 30547274
[TBL] [Abstract][Full Text] [Related]
16. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.
Zhao Q; Qian Q; Cao D; Yang J; Gui T; Shen K
J Ovarian Res; 2018 Apr; 11(1):31. PubMed ID: 29685168
[TBL] [Abstract][Full Text] [Related]
17. Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.
Yang Y; Qiu JG; Li Y; Di JM; Zhang WJ; Jiang QW; Zheng DW; Chen Y; Wei MN; Huang JR; Wang K; Shi Z
Am J Transl Res; 2016; 8(9):3986-3994. PubMed ID: 27725879
[TBL] [Abstract][Full Text] [Related]
18. Retraction: MicroRNA-27 Inhibits Autophagy and Promotes Proliferation of Multiple Myeloma Cells by Targeting the NEDD4/Notch1 Axis.
Frontiers Editorial Office
Front Oncol; 2021; 11():840086. PubMed ID: 35036359
[TBL] [Abstract][Full Text] [Related]
19. Models to investigate intussusceptive angiogenesis: A special note on CRISPR/Cas9 based system in zebrafish.
Vimalraj S; Saravanan S; Anuradha D; Chatterjee S
Int J Biol Macromol; 2019 Feb; 123():1229-1240. PubMed ID: 30468812
[TBL] [Abstract][Full Text] [Related]
20. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
[Next] [New Search]
